AI in Precision Oncology
AI in Precision Oncology is more than a scientific or medical journal; it is a mission-driven initiative to harness the power of AI in improving oncology care.” – Dr. Douglas Flora, Editor-in-Chief
AI in Precision Oncology is the only peer-reviewed journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology. Spearheaded by Editor-in-Chief Douglas Flora, MD and supported by a diverse and accomplished team of international experts, the Journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field.
The use of AI in oncology has the potential to revolutionize cancer care, from early detection to precision medicine. AI can assist in analyzing complex data, such as genomics, imaging, and electronic health records, to improve cancer diagnosis and treatment planning. Moreover, AI can help predict treatment responses, identify new drug targets, and facilitate clinical trials. The Journal's scope includes all aspects of AI in oncology, from basic research to clinical implementation.
AI in Precision Oncology publishes original research articles, reviews, and perspectives on the application of artificial intelligence (AI) in cancer research, diagnosis, and treatment, bringing together researchers, clinicians, and industry experts to share their knowledge and experience in this rapidly evolving field. The Journal helps professionals in the field of oncology understand how artificial intelligence and technology solutions can be applied in an evidence-based, ethical, and thoughtful manner. Overall, the Journal seeks to promote AI's responsible and effective use in oncology, benefiting both healthcare providers and patients.
AI in Precision Oncology coverage includes:
AI algorithms for cancer detection, diagnosis, and prognosis
AI-based biomarkers for cancer screening and diagnosis
AI-assisted imaging analysis for tumor detection and segmentation
AI-guided treatment planning and personalized therapy
AI-enabled drug discovery and development
Machine learning and deep learning in cancer research
Natural language processing for electronic health record analysis
Ethical and regulatory issues in AI in oncology
AI in Precision Oncology is under the editorial leadership of Editor-in-Chief Douglas Flora, MD, Executive Medical Director, Oncology Services, St. Elizabeth, and supported by a diverse and accomplished team of experts, including David Penberthy, MD, MBA, Associate Professor of Radiation Oncology, Penn State Health; Nikhil Thaker, MD, Chief Medical Informatics Officer, Arizona Oncology; and Scott Penberthy, Managing Director of AI at Google.
| Blythe Adamson, PhD, MPH | Flatiron Health, New York, NY, USA |
| Olalekan Ajayi, PHARMD, MBA, FACCC | Highlands Oncology Group, Springdale, AR, USA |
| Sana Al-Sukhun | Al Hyatt Oncology Practice, Amman, Jordan |
| Christopher Banerji, PhD | Alan Turing Institute, London, United Kingdom |
| Larry Bilbrey | Tennessee Oncology/Oneoncology, Nashville, TN, USA |
| Piotr Borkowski, MD | Quest Diagnostics / Ameripath, Tampa, FL, USA |
| Harvey Castro, MD, MBA | Medical Intelligence Ops, Flower Mound, TX, USA |
| William Cho, PhD, RCMP | Queen Elizabeth Hospital, Kowloon, Hong Kong |
| Kundan Singh Chufal | Rajiv Gandhi Cancer Inst & Research Ctr, New Delhi, India |
| Ezra Cohen, MD | Tempus, Chicago, IL, USA |
| Kevin Davies, MD | Washington, DC, USA |
| Jeroen De Ridder, PhD | University Medical Center Utrecht, Utrecht, Netherlands |
| Adam P Dicker, MD, PhD | Thomas Jefferson University, Philadelphia, PA, USA |
| Douglas Flora, MD | St Elizabeth Healthcare, Edgewood, KY, USA |
| Daniel Flora, MD, PHARMD | St. Elizabeth Healthcare, Edgewood, KY, USA |
| George Gemelos, PhD | Vancouver, WA, USA |
| Bethany Hills Grois, JD, MPH | White & Case Llp, New York, NY, USA |
| Leroy Hood, MD, PhD | Phenome Health & Isb, Seattle, WA, USA |
| Sanjay K Juneja, MD | Tempus Ai, Baton Rouge, LA, USA |
| Toufic Kachaamy, MD, FASGE, AGAF, FACG | City Of Hope, Goodyear, AZ, USA |
| Sean Khozin, MD, MPH | Ceo Roundtable On Cancer&Project Data Sphere, Morrisville, NC, USA |
| Teri Klein, PhD | Stanford University, Stanford, CA, USA |
| Jill Kolesar, PHARMD | University of Kentucky, Lexington, KY, USA |
| Jeanne Kowalski, PhD | University of Texas at Austin, Austin, TX, USA |
| Constance Lehman, MD, PhD | Harvard Medical School, Boston, MA, USA |
| Jana Lipkova, PhD | University of California Irvine, Irvine, CA, USA |
| Arturo Loaiza-Bonilla, MD, MSED | Massivebio, New York, NY, USA |
| Amin Mazloom, PhD | Exact Sciences, La Jolla, CA, USA |
| Sarah Mcgough, PhD | Genentech Inc, South San Francisco, CA, USA |
| Vishisht Mehta, MBBS, FCCP, DAABIP | Lung Center Of Nevada, Henderson, NV, USA |
| Mike Montalto, PhD | Amgen Inc, Thousand Oaks, CA, USA |
| Timothy N Showalter, MD, MPH | University of Virginia, Charlottesville, VA, USA |
| Mika Newton, BS | Xcures Inc, Oakland, CA, USA |
| David R Penberthy, MD, MBA | University of Virginia, Charlottesville, VA, USA |
| Scott Penberthy, PhD | Google Cloud, Palo Alto, CA, USA |
| Sylvia Plevritis, PhD | Stanford University, Stanford, CA, USA |
| Oscar Puig, PhD | Chicago, IL, USA |
| Krishnan R Patel, MD | National Cancer Institute, Bethesda, MD, USA |
| Rajeev Ronanki, MS | Miami Beach, FL, USA |
| Nihal El Rouby Pharmd, PhD | University of Cincinnati, Cincinnati, OH, USA |
| Afreen Shariff, MD | Duke University School of Medicine, Durham, NC, USA |
| Brad G Somer, MD, MBA | West Cancer Center & Research Institute, Germantown, TN, USA |
| Vivek Subbiah, MD | Sarah Cannon Research Inst (Scri), Nashville, TN, USA |
| Luma Tabbaa, PhD | University Of Kent, Kent, United Kingdom |
| Nikhil G Thaker, MD, MHA, FABS | Capital Health, Pennington, NJ, USA |
| David Waterhouse, MD, MPH | Oncology Hematology Care Inc, Cincinnati, OH, USA |